Head-to-head evidence
tulisokibart vs XmAb942
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: TL1A · full Ulcerative Colitis pipeline
tulisokibart
Developed by Merck & Co.
NCT06052059 · Phase 3 · active, not recruiting
First Ph3 induction win for any anti-TL1A; met primary + key secondaries (June 2026).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2037 · NCT06651281 (registry estimate)
XmAb942
Developed by Xencor
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT06619990 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: tulisokibart's landscape · XmAb942's landscape